SCY-770 — Initial data
H2 2027
A Phase 2 proof-of-concept study of SCY-770 in ADPKD patients is anticipated to begin in Q4 2026 with an early efficacy readout anticipated in the second half of 2027Source filing
SCYX biotech catalysts & pipeline
SCYNEXIS INC · Data as of 2026-10-25